MedTrace Logo

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

NCT03786926 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-06-26

Study results available
· View outcomes & findings →

Summary

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

Conditions

Interventions

DRUG

HMPL-689

HMPL-689 is a PI3Kδ inhibitor

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Claudia Huang · Hutchmed Limited

  • Nilanjan Ghosh, MD · Atrium Health Levine Cancer Institute

  • Jonathan B Cohen, MD · Emory Winship Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2024-06-26
Completion
2024-06-26
FDA Drug
Yes

Countries

  • United States
  • Finland
  • France
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786926 on ClinicalTrials.gov